Cleaning validation and verification in a high potent granulation suite

Published: 17-Nov-2022 Featured companies: PCI Pharma Services
Manufacturing Dosage Forms

Download the roundtable discussion for free

When manufacturing highly potent solid oral dosage forms, taking an effective approach to cleaning the equipment used is paramount. Manufacturing Chemist Editor Dr Kevin Robinson recently caught up with PCI Pharma Services process experts Ben Potter, Amala Alex and Richard Parry to learn more about cleaning validation and verification, the differences between the two … and why they’re so important. 

Download the roundtable discussion today. 

Featured companies

PCI Pharma Services: Your bridge between life-changing therapies and patients.
See more

You may also like

Manufacturing

Ultra-high potency and its impact on pharmaceutical outsourcing

Read more
This article explores the emerging distinction between high and ultra-high potency APIs, highlighting the implications for pharmaceutical outsourcing and risk management in an evolving therapeutic landscape

Trending Articles

  1. Ultra-high potency and its impact on pharmaceutical outsourcing This article explores the emerging distinction between high and ultra-high potency APIs, highlighting the implications for pharmaceutical outsourcing and risk management in an evolving therapeutic landscape
  2. PCI Pharma Services PCI Pharma Services: Your bridge between life-changing therapies and patients.
  3. LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
  4. New thermal inkjet printer expands AM Labels’ coding portfolio M2 system delivers high resolution variable data printing at production-line speeds
  5. Why aseptic processing is critical for microsphere drug manufacturing As microsphere-based drug delivery systems move from niche innovation to commercial reality, manufacturers face growing pressure to guarantee sterility without compromising product integrity. Aseptic processing has become essential to meeting both regulatory expectations and patient safety requirements

Relevant companies

See more

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Manufacturing

Ultra-high potency and its impact on pharmaceutical outsourcing

This article explores the emerging distinction between high and ultra-high potency APIs, highlighting the implications for pharmaceutical outsourcing and risk management in an evolving therapeutic landscape
Manufacturing

The changing face of pharma outsourcing

CDMOs are evolving from service providers to strategic partners driving innovation and speed in drug development
Manufacturing

Agility, scale and trust: the outsourcing model driving pharma forward

Outsourcing in the pharmaceutical industry has long been viewed as a matter of convenience and a way to ease short-term capacity pressures or delay the decision to invest in costly new facilities. That framing no longer fits
Manufacturing

At BIO Show in Boston, PCI Pharma Services to provide updates on new manufacturing facility

For leading CDMO, qualification activities for plant’s state-of-the-art sterile fill-finish and lyophilisation line are underway, with GMP production commencing summer 2025
Manufacturing

Targeted protein degraders: transforming oral therapeutics

Targeted protein degraders (TPDs) are redefining modern drug discovery and development, offering a revolutionary approach to treating diseases that were once considered to be untreatable
Manufacturing

PCI Pharma Services acquires Ajinomoto Althea, makes ground on US and European expansion

PCI's acquisition of US-based sterile fill-finish CDMO Ajinomoto Althea is part of the company's overarching strategy to expand its drug delivery services within the US and Europe
Manufacturing

PCI Pharma Serives acquires US-based sterile fill-finish CDMO, Ajinomoto Althea

This acquisition will add antibody-drug conjugate (ADC) manufacturing and US-based sterile fill-finish production capabilities to PCI's portfolio
Subscribe now